Uncategorized Archives - Page 65 of 145

ThursdayDec 02, 2021 9:30 am

Study Finds That Holiday Season May Worsen Mental Health

A recent study conducted by the National Alliance of Mental Illness has found that symptoms of mental illness may worsen during the holiday season. Participants who were part of the study who suffered from various mental health conditions admitted that their conditions worsened during the holiday season. Pamela Mairs, a licensed psychologist who was part of the study, stated that the coronavirus pandemic had on its own triggered increased mental health conditions in adults. She explained that hopelessness, fear about the future, anxiety, withdrawal and depression had been observed in adults. The CDC recently released a guide for the holiday…

ThursdayDec 02, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

Report notes significant and swift advancements in company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period…

WednesdayDec 01, 2021 9:30 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Releases Q3 Update, Details JHU Five-Year Research Agreement

Mydecine’s recent Q3 update includes the company’s five-year research agreement with Johns Hopkins University School of Medicine, which will cover clinical research related to the therapeutic use of psychedelics Mydecine has also filed for various patents on proprietary compounds within the company’s IP portfolio In addition, an updated version of the company’s virtual health platform, Mindleap 2.0, was released in Q3, enhancing user experience, infrastructure improvement, and expansion of overall content Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), a company that focuses on bio- and digital technology that aims to transform the treatment of mental health and addiction…

TuesdayNov 30, 2021 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Divisional Update Highlights Consistent Program and Product Progress Across the Board

MINDCURE plans to schedule a pre-IND meeting with the FDA for its Desire Project during Q1 2022 with a subsequent Phase 2 trial to begin Q3 2022 The company expects that the GLP supply of ibogaine will be available for distribution to research partners in Q2 2022 Information on MC-106 and MC-808, an expansion of MINDCURE’s drug pipeline, will be released during Q2 2022 As a member of the Digital Therapeutics Alliance, Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) delivers digital therapeutics (“DTx”) that are evidence-based interventions driven by high-quality software to prevent, manage, and treat medical disorders…

TuesdayNov 30, 2021 9:30 am

Money-Related Stress Compromising Young Adults’ Mental Health

A survey conducted by Deloitte has found that many young individuals are experiencing high levels of stress. Of the total population surveyed, about 45% of Gen Z respondents and 40% of Millennials admitted to being stressed most or all of the time. The survey also highlights that high numbers in each group admitted that their financial future was a substantial source of this stress. Financial stress is not a new thing. However, the increasing generational wealth gap complicates things. For example, the cost of purchasing a house today is much higher than the cost when people in our grandparents’ generation…

MondayNov 29, 2021 9:30 am

AI Solutions May Make Screening for Breast Cancer More Affordable, Accessible

Research has found that breast cancer is the most commonly diagnosed cancer in women in India. This type of cancer also takes second place among the most common cancer types around the globe, with figures showing that of the more than 680,000 women who succumb to this fatal cancer annually, some 90,000 are in India. Researchers believe that one of the primary reasons behind the high rate of mortality in India is that symptoms in most patients present during the advanced stages of the ailment. Efforts to increase breast cancer awareness and population-scale screening with methods for early detection could…

MondayNov 29, 2021 9:30 am

RYAH Group Inc. (CSE: RYAH) Releases Overview of UK Cannabis Market

Market analysts place high hopes on the potential of the United Kingdom market Growing demand from patients and patient families brought the country’s medical cannabis program to a tipping point RYAH is committed to providing valuable insight and transforming patient care through big data and artificial intelligence After three years of medical cannabis being legal in the United Kingdom, the country has a total of only three patients with a prescription in the entire public system, noted a recent blog from RYAH Group (CSE: RYAH). The article noted that many more patients receive cannabis-derived medications, including flower and cannabis oil,…

MondayNov 29, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays

People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders There is no denying that food is a…

MondayNov 29, 2021 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs

InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders Preclinical data of INM-088, the company’s…

WednesdayNov 24, 2021 9:30 am

Study Investigates Influence of Ethnicity on Surviving Brain Tumors

New research has found that white British individuals who have been diagnosed with a malignant brain tumor have a higher risk of mortality than those from other ethnicities. The research’s findings were presented at the NCRI Festival. The study assessed the influence of an individual’s ethnicity on their rate of survival of a brain tumor. The researchers found that individuals who are classified under other ethnic groups had 30% lower chances of mortality in one year after being diagnosed with a malignant brain tumor. For the study, Hiba Wanis, a research assistant at King’s College London’s Centre for Cancer, Society…